Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
The interaction between cluster of differentiation 47 (CD47) and signal regulatory protein α (SIRPα) protects healthy cells from macrophage attack, which is crucial for maintaining immune homeostasis. Overexpression of CD47 occurs widely across various tumor cell types and transmits the “don't...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2024-01-01
|
| Series: | Genes and Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304223000028 |
| _version_ | 1797745115870003200 |
|---|---|
| author | Pengcheng Zhao Longyan Xie Lei Yu Ping Wang |
| author_facet | Pengcheng Zhao Longyan Xie Lei Yu Ping Wang |
| author_sort | Pengcheng Zhao |
| collection | DOAJ |
| description | The interaction between cluster of differentiation 47 (CD47) and signal regulatory protein α (SIRPα) protects healthy cells from macrophage attack, which is crucial for maintaining immune homeostasis. Overexpression of CD47 occurs widely across various tumor cell types and transmits the “don't eat me” signal to macrophages to avoid phagocytosis through binding to SIRPα. Blockade of the CD47-SIRPα axis is therefore a promising approach for cancer treatment. Lymphoma is the most common hematological malignancy and is an area of unmet clinical need. This review mainly described the current strategies targeting the CD47-SIRPα axis, including antibodies, SIRPα Fc fusion proteins, small molecule inhibitors, and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma. |
| first_indexed | 2024-03-12T15:19:49Z |
| format | Article |
| id | doaj.art-5a03bb9c854e4aa4a5fe6e906395d940 |
| institution | Directory Open Access Journal |
| issn | 2352-3042 |
| language | English |
| last_indexed | 2024-03-12T15:19:49Z |
| publishDate | 2024-01-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Genes and Diseases |
| spelling | doaj.art-5a03bb9c854e4aa4a5fe6e906395d9402023-08-11T05:34:48ZengKeAi Communications Co., Ltd.Genes and Diseases2352-30422024-01-01111205217Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapyPengcheng Zhao0Longyan Xie1Lei Yu2Ping Wang3School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong 255000, ChinaTongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China; Corresponding author.School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong 255000, China; Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China; Corresponding author. School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong 255000, China.The interaction between cluster of differentiation 47 (CD47) and signal regulatory protein α (SIRPα) protects healthy cells from macrophage attack, which is crucial for maintaining immune homeostasis. Overexpression of CD47 occurs widely across various tumor cell types and transmits the “don't eat me” signal to macrophages to avoid phagocytosis through binding to SIRPα. Blockade of the CD47-SIRPα axis is therefore a promising approach for cancer treatment. Lymphoma is the most common hematological malignancy and is an area of unmet clinical need. This review mainly described the current strategies targeting the CD47-SIRPα axis, including antibodies, SIRPα Fc fusion proteins, small molecule inhibitors, and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma.http://www.sciencedirect.com/science/article/pii/S2352304223000028Cancer treatmentCD47-SIRPα axisHodgkin lymphomaImmunotherapyNon-Hodgkin lymphoma |
| spellingShingle | Pengcheng Zhao Longyan Xie Lei Yu Ping Wang Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy Genes and Diseases Cancer treatment CD47-SIRPα axis Hodgkin lymphoma Immunotherapy Non-Hodgkin lymphoma |
| title | Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy |
| title_full | Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy |
| title_fullStr | Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy |
| title_full_unstemmed | Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy |
| title_short | Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy |
| title_sort | targeting cd47 sirpα axis for hodgkin and non hodgkin lymphoma immunotherapy |
| topic | Cancer treatment CD47-SIRPα axis Hodgkin lymphoma Immunotherapy Non-Hodgkin lymphoma |
| url | http://www.sciencedirect.com/science/article/pii/S2352304223000028 |
| work_keys_str_mv | AT pengchengzhao targetingcd47sirpaaxisforhodgkinandnonhodgkinlymphomaimmunotherapy AT longyanxie targetingcd47sirpaaxisforhodgkinandnonhodgkinlymphomaimmunotherapy AT leiyu targetingcd47sirpaaxisforhodgkinandnonhodgkinlymphomaimmunotherapy AT pingwang targetingcd47sirpaaxisforhodgkinandnonhodgkinlymphomaimmunotherapy |